Chief Financial Officer
“I’m thrilled to support the advancement of TScan’s pipeline across multiple tumor types and bring our innovative therapies to patients who need them.”
Jason Amello is the Chief Financial Officer and Treasurer at TScan Therapeutics. Prior to joining TScan, Jason was the Chief Financial Officer, Treasurer and Secretary at Candel Therapeutics, Inc., where he developed the company’s financial strategy and assisted with business development initiatives. From 2012 to 2022, Jason served as the Chief Financial Officer and Treasurer of Saniona AB, Akebia Therapeutics, Inc., and Ziopharm Oncology Inc. (now Alaunos Therapeutics, Inc.). From 2000 to 2011, Jason held multiple finance leadership positions at Genzyme Corporation (acquired by Sanofi AG), including Senior Vice President and Chief Accounting Officer. He also led the Strategic Financial Services group through which he served as a key advisor on all of Genzyme’s mergers and acquisitions and other strategic transactions. Earlier in his career, Jason spent 10 years in the business advisory and assurance practice at Deloitte. Jason served on the Board of Directors of Acer Therapeutics, Inc. (acquired by Zevra Therapeutics, Inc.) and recently completed a 10-year tenure on the Board of Directors of the New England Baptist Hospital. Jason holds a B.S. in finance/accounting from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.